Archer Materials has delivered successful results from the first stage of its silicon biochip project with imec, showing that the blood potassium graphene device can be built on silicon, which de-risks its supply chain, reduces unit cost, and accelerates the pathway to manufacture and commercialisation. It has also met clinical standards to help get the Biochip regulatory ready.
To find out more on the Biochip milestone, see the ASX release here
Get the latest updates on our breakthrough technologies and research developments. Join thousands of researchers, investors, and technology enthusiasts.
